CLINICAL ROLE -
Pirtobrutinib and BTK Inhibitors in the CLL Treatment Landscape
This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.
Read More
Navigating Drug Resistance in Chronic Myelocytic Leukemia
Opportunities for further optimization of CML management remain.
Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant Setting
New agents can offer a more tailored approach to therapy selection.
Brown Bag Consult®: Melanoma
Melanoma is responsible for 80% of skin cancer deaths.
Updates in Prostate Cancer Treatment
New therapeutics for prostate cancer must continue to be assessed for comparative safety and efficacy, as well as accessibility for patients.